0
Seeking Innovation. Creating
Value.
Collaborating Together.
Medicon Valley Alliance Meeting
5th May 2009
Business Develo...
1
About Pfizer
Business Development
www.pfizer.com/partnering
2
 Pfizer Inc Revenue in 2008: $48.3 billion; essentially flat year over year despite US LOE of Norvasc,
Zyrtec and Campt...
3
The Heart of Our Work….
TM
SPIRIVAMACUGEN
REBIF
ARICEPT
…Is Bringing Quality Medicines to Patients
4
Broad expertise across 10 therapeutic areas
11 products with sales over $1billion*
14 products ranked #1*
Among the ...
5
Our Five Key Strategies
 Refocus and optimize the patent protected portfolio
 Find new opportunities for established p...
6
Pfizer’s Patent Protected Portfolio
More than
300
Discovery
Projects
In Reg.
2
Phase III
25
Phase II
33
Phase I
40
Total...
7
Customer Focus:
The New Business Unit Structure
Business Units
Development
Sales &
Marketing
Manufacturing
Medical
Resea...
8
Research Organization:
Small, Nimble, Empowered
 Our new Research organization, led by Rod MacKenzie, is now responsibl...
9
Strategy
 Deliver a world class pipeline of high value biotherapeutics
 Create and maintain an industry-leading compet...
10
 Single share of voice driven approach to field force deployed
across Europe & US
 Multiple field force deployment mo...
11
Specialty Care Business Unit:
Deliver extraordinary value in the treatment of serious conditions
Products
Thelin™
Pharm...
12
Oncology Business Unit:
Patent Protected Portfolio
 Global Oncology Opportunity:
 $81B by 2012 with 7% CAGR
 Pfizer ...
13
Established Products Business Unit:
Unlocking Value
StrengthsStrengths
 Oral solid dose
FocusFocus
 “Niche” markets
...
14
Source: IMS Market Prognosis March, 2009 (total pharma Market Sales in USD with forecasted exchange rates, at ex-manufa...
15
Pfizer Animal Health:
A Leader in Animal Health
2008 revenue $2.8 billion
4,000+ colleagues worldwide
More than 700 ...
16
Partnering with Pfizer
Worldwide Business
Development
www.pfizer.com/partnering
17
A Long History of Successful Collaborations…
Macugen
Eyetech
Zyrtec
UCB
Zithromax
Pliva
Inspra
Novartis
Genotropin
Gene...
18
…And a Commitment to Flexible Working
Relationships*
Co-Promotion,
Co-Development
Research
Alliances
Out Licenses
Ventu...
19
Working Together to Progress Assets,
Programs and Technologies
Alzheimer’s Disease
Diabetes
Inflammation &
Immunology
O...
20
Increased Focus and Transparency:
Examples of High Priority Deals
Pain
• Adolor: delta opioid receptor agonist
• Icagen...
21
Working With Us
Our Commitment to You: Open communications, transparency
and flexibility – the core of every partnershi...
22
Business Development, Strategy & Innovation
Search &
Evaluation
Bob Bagdorf
Strategic
Alliances
Ruth Keir
Out
Licensing...
23
International Business Development
Current Focus
 IBD…complements global deal efforts in alignment with WWBD
 We stri...
24
Selected International Business Development Projects –
a wide range of Therapy Areas and geographies
Allergy & Respirat...
25
Recent International Business Development Deals
 Antihypertensive combination product
 Building on Pfizer’s presence ...
26
International Business Development Team
Jamsheed
Banaji
Frank
Overtoom
Stephen
Schleier
Brian
Pruitt
Vacant
Alberto
Bia...
27
We’re Ready to Talk
With You
Allergy & Respiratory
Chris Brown
chris.d.brown@pfizer.com
Cardiovascular
Ann Barry
ann.ba...
28
 Pfizer remains committed to partnering opportunities – neither the
current climate nor the proposed Wyeth acquisition...
Upcoming SlideShare
Loading in …5
×

Growing in Latin America through Branded Generics Business ...

2,389 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,389
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
104
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Growing in Latin America through Branded Generics Business ...

  1. 1. 0 Seeking Innovation. Creating Value. Collaborating Together. Medicon Valley Alliance Meeting 5th May 2009 Business Development www.pfizer.com/partnering
  2. 2. 1 About Pfizer Business Development www.pfizer.com/partnering
  3. 3. 2  Pfizer Inc Revenue in 2008: $48.3 billion; essentially flat year over year despite US LOE of Norvasc, Zyrtec and Camptosar  R&D expenses: $7.5 billion  Animal Health Sales in 2008: $2.8 billion, 7% growth We Are Truly a Global Company * #1 in terms of sales Source: IMS MAT 1Q08 #2 in Japan $3.6B #1 in Australia $1.0B #1 US $19.0 B #4 Africa / Middle East $0.8B #2 in Europe $13.6B #1 in Latin America $1.9B
  4. 4. 3 The Heart of Our Work…. TM SPIRIVAMACUGEN REBIF ARICEPT …Is Bringing Quality Medicines to Patients
  5. 5. 4 Broad expertise across 10 therapeutic areas 11 products with sales over $1billion* 14 products ranked #1* Among the largest, most admired Field Force globally #1 in US 13 years in a row 100 million patients treated annually Demonstrated expertise and commitment to working collaboratively with our partners *IMS Mat 2Q2008 Working Together for a Healthier World
  6. 6. 5 Our Five Key Strategies  Refocus and optimize the patent protected portfolio  Find new opportunities for established products  Grow in emerging markets  Invest in complementary businesses  Instill a culture of innovation and continuous improvement Our Path Forward Applying Innovative Science
  7. 7. 6 Pfizer’s Patent Protected Portfolio More than 300 Discovery Projects In Reg. 2 Phase III 25 Phase II 33 Phase I 40 Total 100  Accelerating Pipeline with sharpened focus on key disease areas  Strong flow of medicines expected to progress from Phase II to Phase III  12 Phase III starts from March 2008 to March 2009 Current Pipeline For reference use only, not for external distribution. Updated Apr 2009
  8. 8. 7 Customer Focus: The New Business Unit Structure Business Units Development Sales & Marketing Manufacturing Medical Research Biotherapeutic and Bioinnovation Center Business Units and Leaders:  Primary Care Business Unit: Olivier Brandicourt  Specialty Care Business Unit: Paul Richardson  Oncology Business Unit: Garry Nicholson  Established Products Business Unit: David Simmons  Emerging Markets Business Unit: Jean-Michel Halfon  Animal Health Business Unit: Juan-Ramon Alaix Business Development
  9. 9. 8 Research Organization: Small, Nimble, Empowered  Our new Research organization, led by Rod MacKenzie, is now responsible for programs from idea to positive Proof of Concept. It is composed of smaller Research Units led by empowered and accountable Chief Scientific Officers (CSOs)  Research Units include:  CVMED  Neuroscience  Inflammation/Immunology  Oncology  Allergy & Respiratory  Pain  Antibacterials  Vaccines  Regenerative Medicines  Indications Discovery  Genitourinary  Antivirals  Our Research & Development Organization is supported by Partner Lines including  Pharmaceutical Sciences  Drug Safety  Development Operations  Regulatory Affairs and Quality Assurance
  10. 10. 9 Strategy  Deliver a world class pipeline of high value biotherapeutics  Create and maintain an industry-leading competitive advantage through technology innovation  Lower clinical attrition and decrease development time Delivering a steady pipeline of biotherapeutics, based on key biologic modalities and novel, validated disease targets  1st Horizon: Monoclonal Antibodies (MAbs)  2nd Horizon: Peptides using alternative scaffold (CovX-bodies)  3rd Horizon: RNAi & Anti-sense  4th Horizon: Stem Cells Pfizer Biotherapeutics and Bioinnovation Center: A Unique, Innovative Strategy to Establish Leadership in BioTx Mission  Propel Pfizer to the forefront of bioinnovation and into the top-tier of biotherapeutics companies
  11. 11. 10  Single share of voice driven approach to field force deployed across Europe & US  Multiple field force deployment models, tailored to meet local market conditions (Deployment differs in open vs. closed access)  Customer segmentation by brand  Customer segmentation across Primary Care  National strategies and national planning that informed local execution  Fully leveraged local market knowledge and true “bottom-up” planning to inform strategies  Centralized marketing budget and review committee process  Earmarked local marketing funds and review committee latitude needed to pursue local promotional opportunities  Standard set of marketing offerings for each brand  “Menu” of customer offerings for each brand, deployed in locally appropriate configuration From To Centered on Micro-markets Customer Centric Nimble Adaptive Adept at Finding Opportunities Focused Innovative Primary Care: Our New Structure Offers Strong Benefits
  12. 12. 11 Specialty Care Business Unit: Deliver extraordinary value in the treatment of serious conditions Products Thelin™ Pharmacy Academic medical centers Scientifically-oriented specialists Customers Spirit of a start-up Entrepreneurial Customer- focused Agile Innovative Culture Deliver Extraordinary Value • Maximize our current portfolio through strong customer focus • Successfully develop all pipeline assets • Build our portfolio by becoming a partner of choice
  13. 13. 12 Oncology Business Unit: Patent Protected Portfolio  Global Oncology Opportunity:  $81B by 2012 with 7% CAGR  Pfizer Oncology products $1.3B 1H2008  Pfizer Assets and Advantages:  Among top Oncology field forces  #1 in Oncology Account Management for customer focus and innovative value added program *  PfizerOncology.com – 24/7 access to Pfizer oncology resources for healthcare professionals  Pfizer Strategy:  Created Business Unit focused on Oncology led by Garry Nicholson, General Manager Oncology  Pursue continuous cycle of new indications in different tumor types  Accelerate clinical trial enrollment & execution  Supplement with business development  Leverage biotech assets * Towers Perrin Largest Oncology Pipeline with 22 compounds in development Four Research PlatformsFour Research PlatformsFour Research PlatformsFour Research Platforms IMMUNO- THERAPY IMMUNO- THERAPY Reawakens immune system Reawakens immune system ANTI- ANGIOGENESIS ANTI- ANGIOGENESIS Blocks growth of tumor blood vessels Blocks growth of tumor blood vessels CYTOTOXIC/ POTENTIATORS CYTOTOXIC/ POTENTIATORS Exploit defects in repair and cycle cells Exploit defects in repair and cycle cells SIGNAL TRANSDUCTION INHIBITORS SIGNAL TRANSDUCTION INHIBITORS Blocks cancer growth signals Blocks cancer growth signals
  14. 14. 13 Established Products Business Unit: Unlocking Value StrengthsStrengths  Oral solid dose FocusFocus  “Niche” markets  Product enhancements and reformulations  Late stage lifecycle planning  Oral solid dose FocusFocusFocusFocus  “Niche” markets  Product enhancements and reformulations  Late stage lifecycle planning A leader in the LOE Market1111 Outpace market growth 2222 A leading provider of low cost medicines 3333 GoalsGoalsGoalsGoals  Brand equity and breadth  Product quality and reliability  Global presence  Technology innovation  Partnerships  Experienced local talent
  15. 15. 14 Source: IMS Market Prognosis March, 2009 (total pharma Market Sales in USD with forecasted exchange rates, at ex-manufacturer prices) Emerging Markets: A Driving Force of Future Growth India: 15% Japan: 5% Germany: -1% France: 0% UK: 1% Brazil: 10% Mexico: 6% US: 4% China: 20% Russia: 23% Turkey: 16% Italy: -1% Absolute Growth in Developed Markets by 2012: $35B (DM Average CAGR: 2%) Absolute Growth in Emerging Markets by 2012: $71B (EM Average CAGR: 10%) Projected Total Market Size for Emerging Markets by 2012: $233B
  16. 16. 15 Pfizer Animal Health: A Leader in Animal Health 2008 revenue $2.8 billion 4,000+ colleagues worldwide More than 700 colleagues are veterinary R&D scientists and specialists Operations in 60 countries Products and services in livestock, poultry and companion animal We’re focused on disease prevention through our portfolio of animal vaccines and animal prescription medicines.
  17. 17. 16 Partnering with Pfizer Worldwide Business Development www.pfizer.com/partnering
  18. 18. 17 A Long History of Successful Collaborations… Macugen Eyetech Zyrtec UCB Zithromax Pliva Inspra Novartis Genotropin Genentech Aricept Eisai Camptosar Daiichi/ Yakult Lipitor Warner Lambert Celebrex G.D. Searle Spiriva BI Rebif Serono Syk tyrosine kinase inhibitors Rigel Allergic Asthma Dalbavancin Vicuron Anti-infectives CCR2 antagonists Incyte RA, Diabetes RAGE inhibitors TransTech Alzheimer’s Disease RTP-801 Quark Age-related Macular Degeneration PipelineLaunched/Approved 1980s 1990s 2000s Eraxis Vicuron Fesoterodine Schwarz Pharma Apixaban Bristol-Myers Squibb CV/Metabolic ST-04, ST-03 Scil Inflammation Dimebon Medivation Alzheimer’s Disease Thelin Encysive
  19. 19. 18 …And a Commitment to Flexible Working Relationships* Co-Promotion, Co-Development Research Alliances Out Licenses Venture Investments *Represents a sampling of creative deal structures Pfizer has completed. Deals listed may fit into more than one category noted above Adolor Boehringer Ingelheim Bristol-Myers Squibb Eisai Eyetech Medivation Serono Bioren BioRexis Coley CovX Encysive Esperion Idun Meridica PowderMed Rinat Serenex Eisai Insite Archemix Abgenix Direvo FivePrime Hydra Icagen Medarex Melior MorphoSys Noxxon Renovis Scripps Tacere Mergers & Acquisitions Aureon Avid Radio- pharmaceuticals Aviir Entelos Evolution Benefits Genomic Health Handylab HD Biosciences M2s Nodality Supplyscape Incubator Fabrus RGo Wintherix Licenses Bayer Celldex Cytos FivePrime Incyte Kosan Quark Rigel Schwarz Scil Sigma Tau Taisho Tacere TransTech Xoma Small molecules Biotherapeutics
  20. 20. 19 Working Together to Progress Assets, Programs and Technologies Alzheimer’s Disease Diabetes Inflammation & Immunology Oncology Pain Psychosis Biotherapeutics Vaccines Science & Technologies (Discovery Platform Lines, Drug Safety R&D, Pharmacokinetics, Dynamics and Metabolism) Asthma COPD Genitourinary Infectious Disease Ophthalmology Smoking Cessation Thrombosis Transplant Ex-US Opportunities Areas of Interest Types of Relationships Licensing Co-Development / Co- Promotion Alliances Venture Investments M&A Out Licensing See appendix for additional detail.
  21. 21. 20 Increased Focus and Transparency: Examples of High Priority Deals Pain • Adolor: delta opioid receptor agonist • Icagen: sodium ion channels • Rinat: RN624 • Renovis: VRI antagonists • Hydra Biosciences: TRPV3 Diabetes • Bayer: BAY 74-4113 • CovX: platform technology Alzheimer’s Disease • Medivation: dimebon • Rinat: RN1219 • Transtech: TTP-4000/TTP-488 Oncology • Celldex: CDX-110 • Serenex: HSP-90 Inhibitors • Coley: vaccines • CovX: platform technology Inflammation • Incyte: CCR2 antagonists (RA) Schizophrenia • Taisho: mGLuR agonist
  22. 22. 21 Working With Us Our Commitment to You: Open communications, transparency and flexibility – the core of every partnership Our Goal is Simple: Evaluate your asset as if it were our own.
  23. 23. 22 Business Development, Strategy & Innovation Search & Evaluation Bob Bagdorf Strategic Alliances Ruth Keir Out Licensing David Rosen Venture Capital Barbara Dalton International / New BD Tony Scullion Transactions Doug Giordano Strategy & Innovation Kristin Peck BBC & Oncology BD Polly Murphy Operations Deb Mangone Business Development, Strategy & Innovation Bill Ringo Leadership team also includes HR, finance and communication partners
  24. 24. 23 International Business Development Current Focus  IBD…complements global deal efforts in alignment with WWBD  We strive to search, identify & execute business development deals focused on: Late stage compounds (Phase 3….Launched) across a broad scope of Therapy Areas – including non-Pfizer’s core areas Broad scope of geographies – any market/region ex-US Variety of deal types – License / Co-Promotion / Co-Marketing Country Specific Deals Multi- Country Deals International Deals & co- development deals Region Specific Deals Multi- Regional Deals
  25. 25. 24 Selected International Business Development Projects – a wide range of Therapy Areas and geographies Allergy & Respiratory  Anti-histamine - Turkey & Mexico  Idiopathic Pulmonary Fibrosis - Ex -US  Respiratory product range – EU, LA & Asia Cardiovascular / Metabolic  Anti-arrhythmic - Ex-US  Antihypertensive combo product - EU markets and Asia  Atrial fibrillation - Ex-US  Connective Tissue Disease - Europe  Diabetes - Ex-US  Gout – Emerging Markets  Osteoporosis - Asia  Statin – Australia Gastrointestinal  Constipation - Ex-US  Irritable Bowel Syndrome Ex-US  PPI - Ex-US Genitourinary  BPH – CEER  Premature Ejaculation - Ex-US Infectious Diseases  Anti-malaria - Africa  HBV - EU Neuroscience  Multiple Sclerosis - Ex-US  Tinnitus - Worldwide Ophthalmology  Glaucoma - EU  Ophthalmology products - Ex- US Pain  Opiod Patch reformulation - Ex- US  Pain reformulation products - Emerging Markets Other  Branded generics - India Screening / Non-Confidential Reviews Confidential Review and assessment Due Diligence Term Sheet Contractsigned
  26. 26. 25 Recent International Business Development Deals  Antihypertensive combination product  Building on Pfizer’s presence in hypertension  Asia deal signed with Japanese Company  Progressing selected other markets Antihypertensive  Malaria is a strategic focus for Africa & the Emerging Market Area  Deal Signed with US company for Africa with ongoing discussions for other markets Anti-malarial  Over 25 further active regional projects  Many different therapy areas  Many different markets / geographies Other  Exciting area of unmet clinical need  Deal Signed for Europe with US company  Ongoing discussions for other markets Connective tissue disease
  27. 27. 26 International Business Development Team Jamsheed Banaji Frank Overtoom Stephen Schleier Brian Pruitt Vacant Alberto Bianchi Vacant Business Unit (BU) focus All Primary Care Specialty Care & Vaccines Emerging Markets Emerging Markets Emerging Markets Emerging Markets Regions (within Business Unit) Japan Europe, Canada, Australia New Zealand Europe, Australia New Zealand Central & Eastern Europe, Russia, Turkey, Israel, Caucar Asia Latin America Africa and Middle East All IBD members have a secondary Therapy Area focus Business Development for the Oncology and Established Products BU’s is handled globally
  28. 28. 27 We’re Ready to Talk With You Allergy & Respiratory Chris Brown chris.d.brown@pfizer.com Cardiovascular Ann Barry ann.barry@pfizer.com Gastrointestinal Chris Brown chris.d.brown@pfizer.com Genito-Urinary Jeff Hurtig jeffrey.hurtig@pfizer.com Infectious Disease Anti-fungals/Anti-virals Alex Chanas alex.chanas@pfizer.com Infectious Disease Anti-infectives/Anti-bacterials Cyndi Green cynthia.d.green@pfizer.com Inflammation Richard Griffiths richard.j.griffiths@pfizer.com Metabolic & Endocrine Disorders Wick Johnson wick.johnson@pfizer.com Bob Knowles robert.knowles@pfizer.com Neuroscience (Neurology/Psychiatry) Tom Heffner thomas.heffner@pfizer.com Oncology Elizabeth Bachert elizabeth.l.bachert@pfizer.com Ophthalmology Stacy Evans stacy.evans@pfizer.com Pain James Kenney james.p.kenney@pfizer.com For BBC Business Development, please contact Polly Murphy Vice President polly.a.murphy@pfizer.com Science & Technology Ruth Keir ruth.keir@pfizer.com Asia Alex Fowkes alex.fowkes@pfizer.com For Venture Investments, please contact: Barbara Dalton Vice President barbara.dalton@pfizer.com For Externalization Opportunities, please contact: David Rosen Executive Director david.k.rosen@pfizer.com For New Business Development, please contact: Tony Scullion Senior Vice President tony.scullion@pfizer.com For International Business Development, please contact: Jamsheed Banaji Senior Director International Business Development jamsheed.banaji@pfizer.com For acquisitions & divestitures please contact: Doug Giordano Vice President doug.giordano@pfizer.com
  29. 29. 28  Pfizer remains committed to partnering opportunities – neither the current climate nor the proposed Wyeth acquisition changes this  The current climate offers some unique investment opportunities  Pfizer remains flexible on deal structure and terms – each deal is different  Hopefully the previous slides have given you an indication of the breadth of type of opportunities we would consider  We look forward to hearing from you Summary and current climate

×